SEMA4A and Autoimmunity: Recently, a Sema4A-neuropilin-1 (Sema4A-NRP1) axis was reported to maintain T regulatory (Treg) cell stability, highlighting this pathway as a potential therapeutic target that could limit Treg-cell-mediated tumor-induced tolerance without inducing autoimmunity [13].